Welcome to our dedicated page for Teva Pharmaceutical Industries SEC filings (Ticker: TEVJF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Teva Pharmaceutical Industries's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Teva Pharmaceutical Industries's regulatory disclosures and financial reporting.
Teva Pharmaceutical Industries executive Mark Sabag, Executive Vice President, International Markets Commercial, reported an option exercise and related share sales. On 12/09/2025, he exercised stock options to buy 118,724 Ordinary Shares at an exercise price of $18.61 per share, increasing his directly held shares.
That same day, he sold 118,724 Ordinary Shares at a weighted average price of $28.748 per share and an additional 98,168 Ordinary Shares at a weighted average price of $28.7026 per share, both through multiple transactions within narrow price ranges. After these transactions, he directly owned 52,828 Ordinary Shares and held no remaining stock options from this grant. Each Ordinary Share may be represented by one American Depositary Share.
Teva Pharmaceutical Industries executive Mark Sabag, Executive Vice President, International Markets Commercial, reported an option exercise and related share sales. On 12/09/2025, he exercised stock options to buy 118,724 Ordinary Shares at an exercise price of $18.61 per share, increasing his directly held shares.
That same day, he sold 118,724 Ordinary Shares at a weighted average price of $28.748 per share and an additional 98,168 Ordinary Shares at a weighted average price of $28.7026 per share, both through multiple transactions within narrow price ranges. After these transactions, he directly owned 52,828 Ordinary Shares and held no remaining stock options from this grant. Each Ordinary Share may be represented by one American Depositary Share.
Teva Pharmaceutical Industries insider plans Rule 144 share sale. A holder has filed to sell 216,892 ordinary shares of Teva through Citigroup Global Markets on the NYSE, with an aggregate market value of $6,230,750.00 as of the notice. Teva had 1,147,282,512 ordinary shares outstanding, providing context for the size of the planned sale.
The securities to be sold were acquired in two ways: 98,168 shares were received on 03/01/2021 in a rollover transaction from Teva Pharmaceutical Industries Limited, and 118,724 shares were obtained via a cashless exercise of stock options, with cash payment dated 12/09/2025. The seller represents that they are not aware of any undisclosed material adverse information about Teva’s current or prospective operations.
Teva Pharmaceutical Industries insider plans Rule 144 share sale. A holder has filed to sell 216,892 ordinary shares of Teva through Citigroup Global Markets on the NYSE, with an aggregate market value of $6,230,750.00 as of the notice. Teva had 1,147,282,512 ordinary shares outstanding, providing context for the size of the planned sale.
The securities to be sold were acquired in two ways: 98,168 shares were received on 03/01/2021 in a rollover transaction from Teva Pharmaceutical Industries Limited, and 118,724 shares were obtained via a cashless exercise of stock options, with cash payment dated 12/09/2025. The seller represents that they are not aware of any undisclosed material adverse information about Teva’s current or prospective operations.
Teva Pharmaceutical Industries reported a planned sale of restricted stock under Rule 144. The filing covers the potential sale of 115,468 ordinary shares through Citigroup Global Markets Inc. on the NYSE, with an aggregate market value of $3,311,131.04. The shares relate to ordinary shares acquired on 12/09/2025 via a cashless exercise of stock options, with cash noted as the form of payment.
The filing states that the person for whose account the securities may be sold represents that they are not aware of any material adverse, non-public information about Teva’s current or prospective operations.
Teva Pharmaceutical Industries reported a planned sale of restricted stock under Rule 144. The filing covers the potential sale of 115,468 ordinary shares through Citigroup Global Markets Inc. on the NYSE, with an aggregate market value of $3,311,131.04. The shares relate to ordinary shares acquired on 12/09/2025 via a cashless exercise of stock options, with cash noted as the form of payment.
The filing states that the person for whose account the securities may be sold represents that they are not aware of any material adverse, non-public information about Teva’s current or prospective operations.
Teva Pharmaceutical Industries director equity update: A Teva director reported the vesting and settlement of 4,804 restricted share units into the same number of ordinary shares on 12/02/2025, shown as an "M" (conversion) transaction. Following this transaction, the director beneficially owns 4,804 ordinary shares, held directly.
These restricted share units were originally granted on December 2, 2024 and vested on December 2, 2025. Each restricted share unit entitled the holder to receive one ordinary share or, at the compensation committee’s option, the cash value of one ordinary share. Teva’s ordinary shares may also be represented by American Depositary Shares, with each ADS currently representing one ordinary share.
Teva Pharmaceutical Industries director equity update: A Teva director reported the vesting and settlement of 4,804 restricted share units into the same number of ordinary shares on 12/02/2025, shown as an "M" (conversion) transaction. Following this transaction, the director beneficially owns 4,804 ordinary shares, held directly.
These restricted share units were originally granted on December 2, 2024 and vested on December 2, 2025. Each restricted share unit entitled the holder to receive one ordinary share or, at the compensation committee’s option, the cash value of one ordinary share. Teva’s ordinary shares may also be represented by American Depositary Shares, with each ADS currently representing one ordinary share.
Teva Pharmaceutical Industries Ltd. director reports share sale. A reporting person serving as a director of Teva Pharmaceutical Industries Ltd. (TEVA) sold 50,000 Ordinary Shares on 11/26/2025 in an open-market transaction coded "S" for sale. The shares were sold at a weighted average price of $26.0301 per share, with individual trades ranging from $26.03 to $26.035.
After this transaction, the reporting person is shown as beneficially owning 445,000 Ordinary Shares indirectly through Swiftcurrent Master Fund Ltd. and 105,315 Ordinary Shares directly. The filing notes that the Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share, and that certain indirect holdings are disclaimed except for any indirect pecuniary interest.
Teva Pharmaceutical Industries Ltd. director reports share sale. A reporting person serving as a director of Teva Pharmaceutical Industries Ltd. (TEVA) sold 50,000 Ordinary Shares on 11/26/2025 in an open-market transaction coded "S" for sale. The shares were sold at a weighted average price of $26.0301 per share, with individual trades ranging from $26.03 to $26.035.
After this transaction, the reporting person is shown as beneficially owning 445,000 Ordinary Shares indirectly through Swiftcurrent Master Fund Ltd. and 105,315 Ordinary Shares directly. The filing notes that the Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share, and that certain indirect holdings are disclaimed except for any indirect pecuniary interest.
Teva Pharmaceutical Industries Ltd. insider plans share sale under Rule 144. A holder has filed to sell 28,229 ordinary shares through Citigroup Global Markets Inc. on the NYSE, with an aggregate market value of $699,523.09. The filing notes that 1,147,282,512 ordinary shares were outstanding at the time of the notice.
The seller acquired 63,492 ordinary shares on 11/20/2025 via restricted stock vesting from Teva as compensation, and payment was characterized as compensation rather than cash. Over the past three months, the same person sold 30,000 ordinary shares on 11/14/2025 for gross proceeds of $753,321.00. By signing, the seller represents they are not aware of undisclosed material adverse information about Teva’s operations.
Teva Pharmaceutical Industries Ltd. insider plans share sale under Rule 144. A holder has filed to sell 28,229 ordinary shares through Citigroup Global Markets Inc. on the NYSE, with an aggregate market value of $699,523.09. The filing notes that 1,147,282,512 ordinary shares were outstanding at the time of the notice.
The seller acquired 63,492 ordinary shares on 11/20/2025 via restricted stock vesting from Teva as compensation, and payment was characterized as compensation rather than cash. Over the past three months, the same person sold 30,000 ordinary shares on 11/14/2025 for gross proceeds of $753,321.00. By signing, the seller represents they are not aware of undisclosed material adverse information about Teva’s operations.
Teva Pharmaceutical Industries Ltd. (TEVA) reported an insider stock sale by its EVP, Head of U.S. Commercial. On 11/14/2025, the executive sold 30,000 Ordinary Shares in an open market transaction at a price of $25.1107 per share, reported under transaction code "S" for a sale. After this transaction, the executive beneficially owns 28,384 Ordinary Shares, held directly. The filing notes that the Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.
Teva Pharmaceutical Industries Ltd. (TEVA) reported an insider stock sale by its EVP, Head of U.S. Commercial. On 11/14/2025, the executive sold 30,000 Ordinary Shares in an open market transaction at a price of $25.1107 per share, reported under transaction code "S" for a sale. After this transaction, the executive beneficially owns 28,384 Ordinary Shares, held directly. The filing notes that the Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.
Teva Pharmaceutical Industries (TEVA) received a Form 144 notice for a planned sale of up to 30,000 ordinary shares. The filing lists an aggregate market value of $753,321, with an approximate sale date of 11/14/2025. The proposed broker is Citigroup Global Markets Inc., and the shares are listed on the NYSE. The seller reports acquiring the shares on 11/20/2024 via a shares from rollover transaction, with the consideration described as compensation.
Teva Pharmaceutical Industries (TEVA) received a Form 144 notice for a planned sale of up to 30,000 ordinary shares. The filing lists an aggregate market value of $753,321, with an approximate sale date of 11/14/2025. The proposed broker is Citigroup Global Markets Inc., and the shares are listed on the NYSE. The seller reports acquiring the shares on 11/20/2024 via a shares from rollover transaction, with the consideration described as compensation.
TEVA Pharmaceutical Industries (TEVA) reported an insider transaction by director Roberto Mignone. On 11/06/2025, he sold 200,000 Ordinary Shares (transaction code S) at a weighted average price of $24.1094.
Following the sale, he beneficially owned 495,000 Ordinary Shares indirectly through Swiftcurrent Master Fund Ltd. and 105,315 Ordinary Shares directly. The filing notes that TEVA’s Ordinary Shares may be represented by ADSs, each currently representing one Ordinary Share.
TEVA Pharmaceutical Industries (TEVA) reported an insider transaction by director Roberto Mignone. On 11/06/2025, he sold 200,000 Ordinary Shares (transaction code S) at a weighted average price of $24.1094.
Following the sale, he beneficially owned 495,000 Ordinary Shares indirectly through Swiftcurrent Master Fund Ltd. and 105,315 Ordinary Shares directly. The filing notes that TEVA’s Ordinary Shares may be represented by ADSs, each currently representing one Ordinary Share.
Teva Pharmaceutical Industries (TEVA) disclosed an insider transaction on Form 4. Chief Accounting Officer Amir Weiss sold 12,300 ordinary shares on 11/06/2025 at a weighted average price of $24.4361, with trades ranging from $24.435 to $24.455. Following the sale, he beneficially owns 17,950 shares, held directly. The filing notes that Teva’s ordinary shares may be represented by ADSs, each currently equal to one ordinary share.
Teva Pharmaceutical Industries (TEVA) disclosed an insider transaction on Form 4. Chief Accounting Officer Amir Weiss sold 12,300 ordinary shares on 11/06/2025 at a weighted average price of $24.4361, with trades ranging from $24.435 to $24.455. Following the sale, he beneficially owns 17,950 shares, held directly. The filing notes that Teva’s ordinary shares may be represented by ADSs, each currently equal to one ordinary share.